Green Cross Wellbeing Successfully Concludes '2026 Pain Management Latest Insights Symposium'
GCGreen Cross Wellbeing announced on July 2 that it held the '2026 GCWB Pain Symposium' at Dragon City Hotel in Yongsan-gu, Seoul, on the 27th of last month, where experts shared the latest treatment strategies and clinical experiences in the field of pain management.
The symposium was chaired by Hyundong Jang, Director of Hyun Hospital, and featured leading experts in pain management as speakers. They shared the latest insights and real-world clinical experiences in the treatment of joint and musculoskeletal pain.
From the top row, left: Hyejun Ahn, Director of Asanbon Rehabilitation Medicine Clinic; Hyunsul Kim, Director of Seoul Anapoon World Clinic; from the bottom row, left: Jaehun Jung, Director of Namgise Hospital; Hyundong Jang, Director of Hyun Hospital; Jinwon Hwang, Director of Anapoon World Clinic are taking a commemorative photo at the '2026 GCWB Pain Forum' held by GC Green Cross Wellbeing at Dragon City Hotel, Yongsan-gu, Seoul on the 27th of last month. GC Green Cross Wellbeing.
View original imageThe main sessions included: ▲ 'Latest Insights on Intra-articular Injection Therapy' by Hyejun Ahn of Asanbon Rehabilitation Medical Clinic; ▲ 'Pain Treatment Using Dr.PRP®' by Jaehun Jung of Namgise Hospital; ▲ 'Next-Generation Pain Solution Apitoxin Injection®' by Jinwon Hwang of Pain-Free World Clinic; and ▲ 'Pain Treatment Using Apitoxin Injection® and Tergazejoo® (Bera Hyaluronidase Alfa)' by Hyunsul Kim of Seoul Pain-Free World Clinic.
In the first session, Hyejun Ahn, Director of Asanbon Rehabilitation Medical Clinic, gave a presentation on 'Latest Insights on Intra-articular Injection Therapy (GC Wellbeing Deoxiju® · GC Wellbeing Collaphil®).' Dr. Ahn presented current research trends in intra-articular injection therapy and shared clinical experiences with polydeoxyribonucleotide (PDRN) and atelocollagen formulations, including practical case studies from actual medical practice.
In the second session, Jaehun Jung, Director of Namgise Hospital, delivered a talk on 'Pain Treatment Using Dr.PRP®.' Dr. Jung explained the mechanisms and clinical utility of platelet-rich plasma (PRP) therapy and shared his experience applying it to patients with various pain conditions.
In the third session, Jinwon Hwang, Director of Pain-Free World Clinic, lectured on 'Next-Generation Pain Solution Apitoxin Injection®.' Dr. Hwang introduced the mechanism of action and clinical application of mellitin and discussed its potential for use in the field of pain management.
Following this, Hyunsul Kim, Director of Seoul Pain-Free World Clinic, gave a presentation on 'Pain Treatment Using Apitoxin Injection® and Tergazejoo® (Bera Hyaluronidase Alfa).' Dr. Kim introduced a variety of clinical cases utilizing both treatment options and shared his perspectives on strategies for pain management.
Chair Hyundong Jang commented, "In the field of pain management, it is important to take a patient-tailored approach based on diverse treatment options and clinical experience. This symposium was a meaningful opportunity to share the latest treatment insights that can be applied in actual clinical settings."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jungyeop Han, Head of GC Green Cross Wellbeing, said, "Through this symposium, there was active discussion on a range of pain management strategies, including intra-articular injection therapy, Dr.PRP®, Apitoxin Injection®, and Tergazejoo® (human recombinant hyaluronidase). We plan to continue academic activities that share the latest treatment information and support patient care through ongoing academic exchange with medical professionals."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.